DGAP-News: Wereldhave Wereldhave finalises the sale of the French office portfolio 14.12.2015 / 18:00 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Schiphol, the Netherlands, 2015-12-14 18:00 CET (GLOBE NEWSWIRE) -- Wereldhave has today successfully completed the sale of the office building 'Le Cap' in Saint Denis, Paris. The office building was sold for total net proceeds of [Eur] 50m, which is [Eur] 5.9m or 13.4% above the book value as at December 31, 2014, and [Eur] 3.4m or 7.3% above the book value as at June 30, 2015. It represents a net exit yield of 5.6%. Net proceeds of the disposal in 2015 of the French portfolio of three office buildings were [Eur] 20.2m in excess of the book-value as at December 31, 2014. This sale also marks the end of the French offices portfolio. The Management Board wishes to express its gratitude to Michel Janet and the Wereldhave France offices team. This transaction brings the pro forma LTV at year-end 2015 in the range of 38-39%. Allez & Associes acted as notary to Wereldhave. Information for the press: Richard W. Beentjes E richard.beentjes@wereldhave.com T + 31 20 702 78 32 Information for analysts: Jaap-Jan Fit E jaapjan.fit@wereldhave.com T + 31 20 702 78 43 Click on, or paste the following link into your web browser, to view the associated documents https://cns.omxgroup.com/cds/DisclosureAttach...mentId=540 618 News Source: NASDAQ OMX --------------------------------------------------------------------------- 14.12.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Wereldhave Netherlands End of News DGAP News Service --------------------------------------------------------------------------- 423553 14.12.2015
DGAP-News: Wereldhave finalises the sale of the French
Top 10 Most Recent News Articles
Pacira BioSciences Faces Shareholder Revolt in M&A Deal
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue ReadingTop 5 Most Recently Viewed Articles
Context Therapeutics Gains Confidence with Strategic Developments
Piper Sandler's Renewed Confidence in Context Therapeutics Piper Sandler has reiterated an Overweight rating for Context Therapeutics (NASDAQ: CNTX), maintaining a price target of $4.50 for the stock. This endorsement underscores their belief in the company’s potential within the biopharmaceutical sector. Positive Data from Competitors Enhances Expectations This renewed...
Continue Reading
Actinium's ATNM-400: A Promising Frontier in Prostate Cancer Therapy
Introduction to ATNM-400's Innovative Approach Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) has announced compelling preclinical data showcasing its innovative treatment, ATNM-400. This first-in-class antibody radioconjugate targets a unique, non-PSMA antigen, revolutionizing prostate cancer therapy. ATNM-400 offers noteworthy therapeutic activity independent of...
Continue Reading
Opportunity Knocks: Ligon's Major Auction Up for Bids
Equipment Auction Offers Unique Buying Opportunity Catch this: Ligon Co.'s auction is like finding a needle in a haystack in a world of overpriced equipment. We're talking about a smorgasbord of heavy machinery up for online grabs, and it’s happening until June 17. Auction Highlights: Your Next Business Asset? From telehandlers to trailers, this ain't your everyday yard...
Continue Reading
Selector Enhances Service Delivery with AWS Marketplace Launch
Selector Launches on AWS Marketplace for Better Accessibility Selector, a pioneer in AI-driven observability and network intelligence, is transforming how organizations manage their network operations. The company has launched its flagship platform on the Amazon Web Services (AWS) Marketplace, which makes it easier for customers to procure and deploy its powerful AI tools...
Continue Reading
Exploring the Surge in Decentralized Energy Storage Growth
Decentralized Energy Storage Market Overview The Decentralized Energy Storage market is gaining remarkable traction, with significant insights indicating a shift towards sustainable energy solutions. Valued at approximately USD 10.88 billion, the market is anticipated to expand to a staggering USD 35.62 billion, exhibiting a compound annual growth rate (CAGR) of 15.98%...
Continue Reading